The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization in the European Union for Eli Lilly’s Foundayo ...
After months of prodding, the European Medicines Agency (EMA) and member states of the European Union have begun taking ...
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
Drug shortages remain a difficult to fix issue for the pharma industry and are an issue that can have devastating results.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results